echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > JPMorgan's annual health summit development and opportunities of China's market in 2020

    JPMorgan's annual health summit development and opportunities of China's market in 2020

    • Last Update: 2020-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    JPMorgan's annual health summit was held in San Francisco from January 13 to 16 As the largest and most informative healthcare investment seminar in the industry, the summit brings together industry leaders, fast-growing emerging enterprises, innovative technology creators and investment professionals Left to right: Song Ruilin, President of China pharmaceutical innovation promotion association, Guan Jinxing, CEO of JPMorgan private bank in Asia and vice chairman of investment bank in Greater China, Huang Guobin, head of global investment bank of JPMorgan The 2020 summit attracted more than 9000 participants and discussed topics such as health care industry outlook, latest technology, investment direction, digital medicine, drug price, population aging, etc More than 500 unlisted and listed companies gave on-site presentation to show the latest trend and future development direction of the medical and health industry During the summit, the "China CEO dinner" hosted by JPMorgan Chase entered the second year this year Industry heavyweight guests from more than 50 Chinese biotechnology and biomedical companies attended the dinner and reception, and jointly discussed the development trend of China's medical and health industry and the latest trends of global capital market During the summit, Huang Guobin, China head of JPMorgan global investment bank, shared his views on China's medical and health industry with us What are the main development trends of China's medical and health industry in 2019? For China's biotechnology industry, 2019 is of great significance 2019 is the tenth year of China's medical system reform The 4 + 7 purchasing policy and other new policies have a profound impact on the original drug price system and are reshaping the competition pattern in the domestic pharmaceutical market We see that China's biotechnology and biomedical industry has shown unprecedented momentum of innovation and global development, and some new products have successfully entered the international market China's capital market is also constantly developing, providing better support for the innovation and development of biotechnology and biomedical industry In 2019, nine unprofitable Chinese biotechnology companies IPO in Hong Kong market This shows that chapter 18a of the Listing Rules of the stock exchange has developed into a stable listing channel, from which biotechnology companies can obtain international capital to promote sustainable innovation In June 2019, the scientific and creative board of Shanghai Stock Exchange officially opened This also ushered in a new era for unprofitable biotechnology companies to raise funds in the secondary market in mainland China, and stimulated the enthusiasm of investors in the primary market for investment in biotechnology companies in the early stage of development How to treat the innovation in the field of medical and health care in China? The Chinese market has unique fundamentals The huge middle class, advanced technical strength and strong policy support and many other factors make the medical and health industry have the strength to continuously launch innovative solutions According to the data of China's national health and Family Planning Commission, China is the second largest pharmaceutical market in the world, and the total scale of China's medical and health industry will reach US $2.4 trillion by 2030 In recent years, the coverage of China's medical and health services has been expanding, the quality has been improving, the health awareness of consumers has gradually increased, and the convenience of regular medical treatment has increased The outline of healthy China 2030 plan released in 2016 aims to guide medical institutions to develop into small and medium-sized cities and rural areas In 2019, the catalogue of industries to encourage foreign investment (2019 version) will include the sub sectors of pharmaceutical and medical health industry The move confirms China's firm commitment to improving the level of medical and health services Prior to that, the Chinese government also expanded the access of foreign investment in related industries We expect that innovation and price pressure will continue to coexist, which will promote biomedical companies to develop new technology platforms and new therapies On the one hand, it may mean higher innovation risks, on the other hand, it may mean considerable opportunities What is the future of China's medical and health industry in 2020? In 2020, we expect that Chinese medical and health enterprises will continue to attract investors' attention in Hong Kong IPO market At the same time, science and Technology Innovation Board will provide support for the development of innovative companies and become a strong catalyst for the long-term development of A-share IPO market Many technology companies are committed to applying their own technical expertise to the medical and health industry, optimizing hospital management processes and equipment distribution and maintenance China has a population of more than 1.4 billion The policy environment encourages the development of AI technology and establishes a huge database The extensive application of advanced technology in China's medical and health industry will help significantly improve efficiency, stimulate more demand and reduce costs The most important point is that in the increasingly competitive environment, biomedical companies should adhere to innovation Enterprises at the forefront of biomedical innovation are likely to attract more funds and get more cooperation opportunities.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.